(Q34728162)

4 August 2017

0 references

Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis (English)

1 reference

4 August 2017

0 references

0 references

ankylosing spondylitis

1 reference

inferred from title

author

Adriana Maria Kakehasi

object named as

Adriana Maria Kakehasi

5

0 references

author name string

Marina Amaral de Ávila Machado

1

1 reference

4 August 2017

Mariana Michel Barbosa

2

1 reference

4 August 2017

Alessandra Maciel Almeida

3

1 reference

4 August 2017

Vânia Eloisa de Araújo

4

1 reference

4 August 2017

Eli Iola Gurgel Andrade

6

1 reference

4 August 2017

Mariangela Leal Cherchiglia

7

1 reference

4 August 2017

Francisco de Assis Acurcio

8

1 reference

4 August 2017

publication date

18 May 2013

1 reference

Rheumatology International

4 August 2017

published in

1 reference

4 August 2017

volume

33

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

2199-2213

1 reference

4 August 2017

cites work

Ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

What is "quality of evidence" and why is it important to clinicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Going from evidence to recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

[Meta-analysis of efficacy of anti-TNF alpha therapy in ankylosing spondylitis patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Adverse effects of biologics: a network meta-analysis and Cochrane overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Methotrexate for ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: A multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Low-dose Infliximab (3 mg/kg) Significantly Reduces Spinal Inflammation on Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis: A Randomized Placebo-controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2772-6

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

21 January 2018

1 reference

12 December 2020

Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials.

1 reference

12 December 2020

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

1 reference

12 December 2020

Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study

1 reference

12 December 2020

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).

1 reference

12 December 2020

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

12 December 2020

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

12 December 2020

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

12 December 2020

Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation

1 reference

12 December 2020

Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement

1 reference

12 December 2020

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial

1 reference

12 December 2020

Indirect comparison of the effects of anti-TNF biological agents in patients with Ankylosing Spondylitis by means of a Mixed Treatment Comparison performed on efficacy data from published randomised, controlled trials

1 reference

12 December 2020

10.1007/S00296-013-2772-6

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1024479511

0 references

1 reference